GlassScriptPhysician profile
Jonathan Paul Hamilton
NPI 1376284794
$15,661.81
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $25.27 · 2024: $257 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $1,233 · Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,530.00 |
| Travel and Lodging | $1,233.14 |
| Food and Beverage | $790.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15,178.42 | 2025 | Carvykti, Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.60 | 2022-2024 | Ofev |
| Amgen INC. | $131.66 | 2024-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $43.84 | 2023-2024 | Trelegy Ellipta, Nucala |
| Xeris Pharmaceuticals, INC. | $42.61 | 2024 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $30.74 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Recordati_rare_diseases_inc. | $23.07 | 2024 | Signifor Lar, Isturisa |
| Merck Sharp & Dohme LLC | $22.28 | 2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $22.16 | 2025 | Spravato |
| Abbvie INC. | $16.13 | 2024 | |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.